Skip to main content
NCBI home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1982 Sep 25;285(6345):840–842. doi: 10.1136/bmj.285.6345.840

High serum vitamin B12 binding capacity as a marker of the fibrolamellar variant of hepatocellular carcinoma.

F J Paradinas, W M Melia, M L Wilkinson, B Portmann, P J Johnson, I M Murray-Lyon, R Williams
PMCID: PMC1499744  PMID: 6288165

Abstract

Ten (9.3%) of 107 patients with hepatocellular carcinoma had considerably increased serum unsaturated vitamin B12 binding capacity. All 10 were young (mean 12 years), had no serum alpha-fetoprotein, and no underlying cirrhosis; all had a longer survival compared with patients without increased serum unsaturated vitamin B12 binding capacity in the study. Seven of the 10 patients had fibrolamellar hepatocellular carcinoma, a recently recognised histological variant, which was found in only one young patient without increased serum unsaturated vitamin B12 binding capacity and no alpha-fetoprotein among the remaining 97. This high degree of correlation between increased serum unsaturated vitamin B12 binding capacity and fibrolamellar hepatocellular carcinoma has not been reported before. Increased serum unsaturated vitamin B12 binding capacity may be of considerable help in diagnosis, prognosis, and monitoring treatment of this well-defined group of patients with hepatocellular carcinoma but no alpha-fetoprotein.

Full text

PDF
840

Images in this article

841p841-a
on p.841

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Burger R. L., Waxman S., Gilbert H. S., Mehlman C. S., Allen R. H. Isolation and characterization of a novel vitamin B12-binding protein associated with hepatocellular carcinoma. J Clin Invest. 1975 Nov;56(5):1262–1270. doi: 10.1172/JCI108202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Carmel R., Eisenberg L. Serum vitamin B12 and transcobalamin abnormalities in patients with cancer. Cancer. 1977 Sep;40(3):1348–1353. doi: 10.1002/1097-0142(197709)40:3<1348::aid-cncr2820400352>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  3. Craig J. R., Peters R. L., Edmondson H. A., Omata M. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer. 1980 Jul 15;46(2):372–379. doi: 10.1002/1097-0142(19800715)46:2<372::aid-cncr2820460227>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  4. GOTTLIEBLAU K. S., WASSERMAN L. R., HERBERT V. RAPID CHARCOAL ASSAY FOR INTRINSIC FACTOR (IF), GASTRIC JUICE UNSATURATED B12 BINDING CAPACITY, ANTIBODY TO IF, AND SERUM UNSATURATED B12 BINDING CAPACITY. Blood. 1965 Jun;25:875–884. [PubMed] [Google Scholar]
  5. Kane S. P., Murray-Lyon I. M., Paradinas F. J., Johnson P. J., Williams R., Orr A. H., Kohn J. Vitamin B12 binding protein as a tumour marker for hepatocellular carcinoma. Gut. 1978 Dec;19(12):1105–1109. doi: 10.1136/gut.19.12.1105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Nexo E., Olesen H., Norredam K., Schwartz M. A rare case of megaloblastic anaemia caused by disturbances in the plasma cobalamin binding proteins in a patient with hepatocellular carcinoma. Scand J Haematol. 1975 Jun;14(5):320–327. doi: 10.1111/j.1600-0609.1975.tb02703.x. [DOI] [PubMed] [Google Scholar]
  7. Nexö E., Olesen H., Christensen J. M., Thomsen J., Kristiansen K. Characterization of a cobalamin-binding plasma protein from a patient with hepatoma. Scand J Clin Lab Invest. 1975 Nov;35(7):683–690. doi: 10.1080/00365517509095798. [DOI] [PubMed] [Google Scholar]
  8. Waxman S., Gilbert H. S. A tumor-related vitamin B12 binding protein in adolescent hepatoma. N Engl J Med. 1973 Nov 15;289(20):1053–1056. doi: 10.1056/NEJM197311152892002. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES